The SURMOUNT-OSA results were published and they're remarkable. This is the first large randomized trial of an incretin therapy specifically designed for obstructive sleep apnea, and the results exceeded expectations. Trial Design: - Two parallel trials: patients with moderate-severe OSA who refused/couldn't tolerate CPAP (Trial 1) and patients using CPAP (Trial 2) - Tirzepatide 10mg or 15mg vs. placebo, 52 weeks - Primary endpoint: change in AHI (apnea-hypopnea index) - BMI >=30, AHI >=15 events/hour Trial 1 Results (no CPAP): - Baseline mean AHI: 51.5 events/hour (severe OSA) - Tirzepatide AHI reduction: -25.3 events/hour (vs. -5.3 placebo) - That's a 49% AHI reduction - 43% of tirzepatide patients achieved AHI <15 (mild or no OSA) - 12% achieved AHI <5 (essentially cured) - Mean weight loss: -18.1% Trial 2 Results (with CPAP): - Baseline mean AHI: 49.5 events/hour - Tirzepatide AHI reduction: -29.3 events/hour (vs. -5.5 placebo) - 58% achieved AHI <15 - 21% achieved AHI <5 - Mean weight loss: -19.4% Key secondary endpoints (both trials): - Oxygen desaturation index: reduced ~50% - Nocturnal hypoxemia (% time SpO2 <90%): reduced ~65-70% - Patient-reported sleepiness (ESS score): improved by 4-5 points - Systolic blood pressure: reduced 7-10 mmHg - hs-CRP: reduced ~55% These are CPAP-level improvements from a weekly injection. The sleep medicine field is having a reckoning. For context, CPAP typically reduces AHI by 70-90% when used consistently. Tirzepatide achieved ~50% AHI reduction. It's not a CPAP replacement for severe OSA, but for moderate OSA or for the ~50% of patients who can't tolerate CPAP, this is transformative. Thoughts from fellow sleep physicians?

As a board-certified sleep medicine physician, I have mixed feelings. The data is outstanding, but I want to temper the enthusiasm with clinical reality: What excites me: 1. For the CPAP-intolerant population (which is HUGE — adherence rates for CPAP are 40-60% at best), we finally have an effective alternative. 2. The improvement in nocturnal hypoxemia is particularly important. Time spent with SpO2 <90% is the metric most strongly associated with cardiovascular risk in OSA. A 65-70% reduction is clinically significant. 3. The blood pressure reduction suggests cardiovascular risk modification beyond just AHI. What concerns me: 1. AHI <15 is "mild or no OSA" but it's NOT resolution. Many of these patients still have 10-14 events/hour, which means intermittent hypoxia is ongoing. CPAP eliminates events almost entirely. 2. Only 12-21% achieved AHI <5. So 80-88% of treated patients still have residual OSA. They're better, but not cured. 3. The trial excluded patients with AHI >65. The most severe OSA patients (AHI 70-100+), who are at highest cardiovascular risk, weren't studied. 4. What happens when the drug is stopped? OSA is a structural/anatomical condition. Weight regain = AHI return. These patients need lifelong therapy. My clinical approach going forward: - Moderate OSA (AHI 15-30) + obesity + CPAP-intolerant → tirzepatide is a game-changer - Severe OSA (AHI >30) → CPAP remains first-line, consider adding tirzepatide as adjunct - Any OSA + CPAP-adherent → continue CPAP, add tirzepatide for weight management and potential CPAP pressure reduction

I have to share my personal experience here because this data validates what happened to me (though I was on semaglutide, not tirzepatide). Diagnosed with severe OSA in 2021. My numbers: - AHI: 62 events/hour (severe) - Lowest SpO2: 71% (dangerously low) - BMI: 42 - Epworth Sleepiness Scale: 18/24 (severe daytime sleepiness) Started CPAP at 14 cmH2O. I HATED it. Claustrophobic, air swallowing, mask leaks, dry mouth. Tried 4 different masks. Average usage: 3.2 hours/night (below the 4-hour Medicare threshold). Started semaglutide in January 2024 (for T2D + obesity). Lost 55 lbs over 10 months. My sleep doc repeated my sleep study in November 2024: - AHI: 18 events/hour (now mild-moderate, was severe) - Lowest SpO2: 86% - BMI: 34 - ESS: 8/24 My CPAP pressure was reduced from 14 to 8 cmH2O. At the lower pressure, I can actually tolerate it. My average usage went from 3.2 to 6.1 hours/night because it's so much more comfortable at 8 versus 14. So the weight loss didn't cure my OSA, but it made CPAP tolerable. That's a massive quality-of-life win that the AHI numbers alone don't capture.

this is a perfect illustration of the synergy between GLP-1 therapy and CPAP. Your case demonstrates several important points: 1. Pressure reduction with weight loss. The general rule of thumb is ~2-3 cmH2O pressure reduction per 10% body weight loss. You lost ~20% body weight and needed 6 cmH2O less. That's right on track. 2. CPAP adherence improves at lower pressures. The #1 reason for CPAP non-adherence is pressure intolerance. High pressures cause aerophagia (air swallowing), mask leak, and discomfort. Every cmH2O you drop improves tolerance. 3. You still need CPAP. AHI 18 is still clinically significant OSA — that's 18 apneas and hypopneas per hour, which means your brain is being aroused from sleep 18 times per hour. But at least now you're actually using the CPAP that treats it. For the clinicians: this is why I advocate for GLP-1 therapy as CPAP-adjunctive rather than CPAP-replacement in severe OSA. The goal isn't to eliminate CPAP — it's to make CPAP work better. Timing of repeat sleep studies: I now repeat polysomnography after patients have achieved stable weight loss (usually at 9-12 months on GLP-1 therapy). Earlier studies may underestimate the benefit if weight loss is still ongoing.

I want to add the surgical perspective. I perform uvulopalatopharyngoplasty (UPPP), genioglossus advancement, and hypoglossal nerve stimulation (Inspire) for OSA. SURMOUNT-OSA changes my practice in two ways: 1. Pre-surgical optimization. For patients considering OSA surgery, weight loss with tirzepatide before surgery could dramatically improve outcomes. Many surgical failures are because the patient's BMI is too high — the soft tissue volume overwhelms the surgical correction. Getting patients from BMI 40 to 32 before surgery could be the difference between success and failure. 2. Potential decrease in surgical volume. If moderate OSA patients can be managed medically with tirzepatide (AHI reduced to <15 in 43% of cases), the surgical pool shrinks. I'm OK with this — surgery should be reserved for patients who fail or can't tolerate medical management. However, I want to push back on the idea that SURMOUNT-OSA makes CPAP or surgery obsolete. OSA has multiple pathophysiological drivers: - Anatomical: Retrognathia, macroglossia, enlarged tonsils, deviated septum - Obesity-related: Pharyngeal fat pad, reduced lung volumes, increased oxygen demand - Neuromuscular: Reduced upper airway dilator muscle tone during sleep - Ventilatory control: High loop gain (unstable respiratory control) Tirzepatide primarily addresses the obesity-related driver. Patients with significant anatomical contributions won't get adequate AHI reduction from weight loss alone. That's likely why only 12% achieved AHI <5 — the remaining contributors to OSA aren't weight-dependent.